Clinical Study
Hearing Assessment after Treatment of Nasopharyngeal Carcinoma with CRT and IMRT Techniques
Table 1
Characteristics of the nasopharyngeal carcinoma patients.
| | Parameter | Patients () (%) | Ears () (%) |
| | Age (y) | | | | Range | 20–76 | | | Median | 50.91 | | | Sex | | | | Male | 65 (70.75%) | | | Female | 27 (29.34%) | | | Stage | | | | I | 10 (10.86%) | 20 (11%) | | II | 39 (42.39%) | 77 (42.31%) | | III | 26 (28.26%) | 52 (28.57%) | | IV | 17 (18.47%) | 33 (18.13%) | | Treatment regimen | | | | RT alone | 45 (48.91%) | 89 (48.9%) | | Chemoradiotherapy | 47 (51.08%) | 93 (51.1%) | | Radiation modalities | | | | 2D CRT | 10 (10.86%) | 19 (10.44%) | | 3D CRT | 28 (30.43%) | 56 (30.77%) | | IMRT | 54 (58.69%) | 107 (58.80%) | | Total radiation dose (Gy) | | | | Range | 59.4–79.2 | | | Mean | 70.86 | | | Cisplatin dose (mg/m2) | | | | Range | 120–670 | | | Mean | 363.55 | | | Postirradiated OME | | | | Yes | | 71 (39.00%) | | No | | 111 (61.00%) |
|
|
OME = otitis media with effusion.
|
